NCT01729403View on ClinicalTrials.gov

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

aleglitazar

150 mcg orally daily, 16 weeks

DRUG

metformin

patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)

DRUG

placebo

orally daily, 16 weeks

Trial Locations (1)

41460

Neuss

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01729403 - A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin | Biotech Hunter | Biotech Hunter